NovaBay Reports Results With NVC-422

NovaBay Pharmaceuticals released results from a Phase I trial studying NVC-422, a non-antibiotic anti-infective that showed in vitro activity against major pathogens, including methicillin-resistant Staphylococcus aureus.

The results show that the compound was safe and well tolerated when topically applied to the lower nasal passages, NovaBay said.

Based on these results, NovaBay has started a second Phase I trial to test the safety of NVC-422 at a higher dose and expects to have results by early 2008.

The company expects to start a Phase IIa study by January 2008 in healthy volunteers who are carriers of Staphylococcus aureus in their nasal passages.